Bristol Myers Squibb announced the Phase III CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell… read more.
Electronic vapor products (EVPs), also known as e-cigarettes or vaping devices, have an allure because of their marketed image as a safer alternative to traditional cigarette smoking and… read more.
On World Asthma Day 2024 the message is clear: “Asthma Education Empowers.” The Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, stresses the… read more.
Use of non-nicotinic cytisinicline appears to help adults abstain from vaping nicotine. Researchers reported their findings on May 6, 2024 in JAMA Internal Medicine. “No medication has been… read more.
Qi “Tony” Zhou, a researcher in Purdue University’s College of Pharmacy has received a $2.4 million grant from the National Institutes of Health to fight lung infections that have established… read more.
Eleven million U.S. adults use e-cigarettes to vape nicotine, and about half of them say that they want to stop, but many have trouble doing so because nicotine… read more.
BeiGene, Ltd. announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use…. read more.
Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours… read more.
While debating the pros and cons of robotically assisted lung transplantation, Albert Jauregui, MD, PhD told attendees at the Annual Meeting and Scientific Sessions of the International Society… read more.
Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase III clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of… read more.
In asthma, the tightening of muscles around the bronchi causes damage to the airway by squeezing and destroying epithelial cells, which promotes the airway inflammation and mucus production… read more.
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
